BioXcel Therapeutics, Inc.BTAIEarnings & Financial Report
Nasdaq
NextMar 31, 2026
BTAI Q3 2025 Key Financial Metrics
Revenue
$98.0K
Gross Profit
$87.0K
Operating Profit
$-14.2M
Net Profit
$-30.9M
Gross Margin
88.8%
Operating Margin
-14518.4%
Net Margin
-31541.8%
YoY Growth
-54.2%
EPS
$-2.18
Financial Flow
BioXcel Therapeutics, Inc. Q3 2025 Financial Summary
BioXcel Therapeutics, Inc. reported revenue of $98.0K for Q3 2025, with a net profit of $-30.9M (-31541.8% margin). Cost of goods sold was $11.0K, operating expenses totaled $14.3M.
Key Financial Metrics
| Total Revenue | $98.0K |
|---|---|
| Net Profit | $-30.9M |
| Gross Margin | 88.8% |
| Operating Margin | -14518.4% |
| Report Period | Q3 2025 |
BioXcel Therapeutics, Inc. Annual Revenue by Year
BioXcel Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $2.3M).
| Year | Annual Revenue |
|---|---|
| 2024 | $2.3M |
| 2023 | $1.4M |
| 2022 | $375.0K |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $376000 | $582000 | $1.1M | $214000 | $366000 | $168000 | $120000 | $98000 |
| YoY Growth | 58.0% | 182.5% | 141.6% | -37.2% | -2.7% | -71.1% | -89.1% | -54.2% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $73.7M | $82.3M | $65.4M | $48.9M | $38.3M | $38.6M | $25.8M | $44.8M |
| Liabilities | $130.2M | $154.7M | $139.7M | $134.5M | $131.4M | $128.7M | $133.5M | $133.7M |
| Equity | $-56.5M | $-72.4M | $-74.3M | $-85.6M | $-93.1M | $-90.2M | $-107.7M | $-88.9M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-26.9M | $-17.7M | $-23.2M | $-16.3M | $-14.8M | $-12.0M | $-12.6M | $-18.8M |